Satellos Bioscience (NASDAQ:MSLE) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Satellos Bioscience (NASDAQ:MSLE) in a research note issued on Wednesday,Benzinga reports. The firm set an “overweight” rating on the stock.

MSLE has been the topic of several other reports. Weiss Ratings assumed coverage on shares of Satellos Bioscience in a report on Wednesday, February 11th. They set a “sell (d-)” rating on the stock. Zacks Research upgraded Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Satellos Bioscience has an average rating of “Hold”.

Satellos Bioscience Price Performance

MSLE stock opened at $9.54 on Wednesday. Satellos Bioscience has a 12-month low of $4.53 and a 12-month high of $13.39. The company has a market capitalization of $147.49 million, a price-to-earnings ratio of -7.95 and a beta of 1.10.

Satellos Bioscience Company Profile

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.